C-8OLTCyclo Therapeutics
cyclodextrin, cholesterol transport, lysosomal cholesterol clearance
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-8OLT
C-8OLTC-8OLTcyclodextrin, cholesterol transport, lysosomal cholesterol clearance
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cyclo Therapeutics cyclodextrin, cholesterol transport, lysosomal cholesterol clearance
Cyclo Therapeutics describes itself as a global, clinical-stage biotechnology company developing medicines for rare and neurological disorders. Its lead asset, Trappsol Cyclo, is a proprietary formulation of hydroxypropyl beta cyclodextrin intended to facilitate transport of accumulated cholesterol out of cellular lysosomes. The company states Trappsol Cyclo is being evaluated for Niemann-Pick Disease Type C1 and Alzheimer’s disease.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Cyclo Therapeutics — Near-term readout · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Modifiers: +5 depth (2 programs at…
Source: Deterministic